Drug intelligence / Profile preview

YPC3

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

YPC3 is an IgG1 mouse monoclonal antibody developed against human pancreatic carcinoma. It has demonstrated selective reactivity with human pancreatic carcinoma tissue, showing no reaction with normal pancreatic tissue. Preclinical studies in nude mice bearing pancreatic carcinoma xenografts indicated its potential for radioimmunolocalization, providing clear scintigraphic visualization of tumors, and for immunotherapy, as administration of YPC3 MAb alone or combined with LAK cells inhibited xenograft growth.

Other names: YPC3 MAbYPC-3 MAbYPC 3 MAb

Beyond the preview

Go deeper on YPC3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YPC3.

Explore the full profile